{"DataElement":{"publicId":"7118711","version":"1","preferredName":"Metastatic Diagnosis Hepatocellular Carcinoma Non-Neoplastic Finding Outcome","preferredDefinition":"The clinical, laboratory or molecular evidence, or absence of evidence of a non-neoplastic disease of a malignant tumor that arises from hepatocytes.","longName":"7115529v1.0:7114205v1.0","context":"OCCPR","contextVersion":"1","DataElementConcept":{"publicId":"7115529","version":"1","preferredName":"Metastatic Diagnosis Non-Neoplastic Finding","preferredDefinition":"Any diagnosis indicating the presence of metastatic disease._Clinical, laboratory or molecular evidence, or absence of evidence of a non-neoplastic disease.","longName":"6841515v1.0:7115527v1.0","context":"OCCPR","contextVersion":"1","ObjectClass":{"publicId":"6841515","version":"1","preferredName":"Metastatic Diagnosis","preferredDefinition":"Any diagnosis indicating the presence of metastatic disease.","longName":"C162221","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Metastatic Diagnosis","conceptCode":"C162221","definition":"Any diagnosis indicating the presence of metastatic disease.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"8EFAFAB2-E712-5A45-E053-F662850A0775","latestVersionIndicator":"Yes","beginDate":"2019-07-31","endDate":null,"createdBy":"KNABLEJ","dateCreated":"2019-07-31","modifiedBy":"ONEDATA","dateModified":"2019-07-31","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"7115527","version":"1","preferredName":"Non-Neoplastic Finding","preferredDefinition":"Clinical, laboratory or molecular evidence, or absence of evidence of a non-neoplastic disease.","longName":"C157510","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Non-Neoplastic Finding","conceptCode":"C157510","definition":"Clinical, laboratory or molecular evidence, or absence of evidence of a non-neoplastic disease.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"9AB6B918-95F3-6DF1-E053-F662850AE039","latestVersionIndicator":"Yes","beginDate":"2019-12-27","endDate":null,"createdBy":"KNABLEJ","dateCreated":"2019-12-27","modifiedBy":"ONEDATA","dateModified":"2019-12-27","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2008556","version":"1","preferredName":"Assessment Results","preferredDefinition":"the results of evaluations of the patient and the patient's disease.","longName":"ASSESS_RESULTS","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B2D08DE9-38BB-7208-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-27","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-27","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"CPTAC: Clinical Proteomic Tumor Analysis Consortium","workflowStatus":"RELEASED","registrationStatus":"Qualified","id":"9AB6B918-9604-6DF1-E053-F662850AE039","latestVersionIndicator":"Yes","beginDate":"2019-12-27","endDate":null,"createdBy":"KNABLEJ","dateCreated":"2019-12-27","modifiedBy":"KNABLEJ","dateModified":"2020-06-14","changeDescription":"6/14/20 jk added CPTAC ESCA Baseline CSI.  2/14/20 jk Released per CPTAC SME (Linda) review and approval.  12/27/19 jk created for CPTAC LIHC baseline CRF.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"7114205","version":"1","preferredName":"Hepatocellular Carcinoma Non-Neoplastic Finding Outcome","preferredDefinition":"A malignant tumor that arises from hepatocytes. Hepatocellular carcinoma is relatively rare in the United States but very common in all African countries south of the Sahara and in Southeast Asia. Most cases are seen in patients over the age of 50 years, but this tumor can also occur in younger individuals and even in children. Hepatocellular carcinoma is more common in males than females and is associated with hepatitis B, hepatitis C, chronic alcohol abuse and cirrhosis. Serum elevation of alpha-fetoprotein occurs in a large percentage of patients with hepatocellular carcinoma. Grossly, hepatocellular carcinoma may present as a single mass, as multiple nodules, or as diffuse liver involvement. Microscopically, there is a wide range of differentiation from tumor to tumor (well differentiated to poorly differentiated tumors). Hepatocellular carcinomas quickly metastasize to regional lymph nodes and lung. The overall median survival of untreated liver cell carcinoma is about 4 months. The most effective treatment of hepatocellular carcinoma is complete resection of the tumor. Lately, an increasing number of tumors have been treated with liver transplantation._Clinical, laboratory or molecular evidence, or absence of evidence of a non-neoplastic disease._The result of an action.","longName":"7114205v1.0","context":"OCCPR","contextVersion":"1","type":"Enumerated","dataType":"CHARACTER","minLength":null,"maxLength":"75","minValue":null,"maxValue":null,"decimalPlace":null,"PermissibleValues":[{"value":"None","valueDescription":"Non-Neoplastic Finding Absent","ValueMeaning":{"publicId":"7114207","version":"1","preferredName":"Non-Neoplastic Finding Absent","longName":"7114207","preferredDefinition":"There is no non-neoplastic finding.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Non-Neoplastic Finding Absent","conceptCode":"C160178","definition":"There is no non-neoplastic finding.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9AB144CE-D783-6FE4-E053-F662850A2278","latestVersionIndicator":"Yes","beginDate":"2019-12-27","endDate":null,"createdBy":"KNABLEJ","dateCreated":"2019-12-27","modifiedBy":"ONEDATA","dateModified":"2019-12-27","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9AB144CE-D79C-6FE4-E053-F662850A2278","beginDate":"2019-12-27","endDate":null,"createdBy":"KNABLEJ","dateCreated":"2019-12-27","modifiedBy":"ONEDATA","dateModified":"2019-12-27","deletedIndicator":"No"},{"value":"Nonalcoholic Steatohepatitis (NASH)","valueDescription":"Nonalcoholic Steatohepatitis","ValueMeaning":{"publicId":"3210796","version":"1","preferredName":"Nonalcoholic Steatohepatitis","longName":"3210796","preferredDefinition":"Fatty replacement and damage to the hepatocytes not related to alcohol use. It may lead to cirrhosis and liver failure.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Nonalcoholic Steatohepatitis","conceptCode":"C84445","definition":"Fatty replacement and damage to the hepatocytes not related to alcohol use. It may lead to cirrhosis and liver failure.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E161-A132-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9AB144CE-D7B0-6FE4-E053-F662850A2278","beginDate":"2019-12-27","endDate":null,"createdBy":"KNABLEJ","dateCreated":"2019-12-27","modifiedBy":"ONEDATA","dateModified":"2019-12-27","deletedIndicator":"No"},{"value":"Other","valueDescription":"Other","ValueMeaning":{"publicId":"5697874","version":"1","preferredName":"Other","longName":"5697874","preferredDefinition":"Different than the one(s) previously specified or mentioned.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Other","conceptCode":"C17649","definition":"Different than the one(s) previously specified or mentioned.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"4A253837-4DE2-5542-E053-F662850A338C","latestVersionIndicator":"Yes","beginDate":"2017-03-07","endDate":null,"createdBy":"ALEYR","dateCreated":"2017-03-07","modifiedBy":"GDEEN","dateModified":"2023-12-28","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9AB144CE-D7BB-6FE4-E053-F662850A2278","beginDate":"2019-12-24","endDate":null,"createdBy":"KNABLEJ","dateCreated":"2019-12-27","modifiedBy":"ONEDATA","dateModified":"2019-12-27","deletedIndicator":"No"}],"ConceptualDomain":{"publicId":"2008526","version":"1","preferredName":"Anatomic Sites","preferredDefinition":"locations or structures in the human body.","longName":"ANAT_SITES","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B1ED0F8B-4D91-332D-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-16","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-16","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"7114204","version":"1","preferredName":"Hepatocellular Carcinoma Non-Neoplastic Finding Outcome","preferredDefinition":"A malignant tumor that arises from hepatocytes. Hepatocellular carcinoma is relatively rare in the United States but very common in all African countries south of the Sahara and in Southeast Asia. Most cases are seen in patients over the age of 50 years, but this tumor can also occur in younger individuals and even in children. Hepatocellular carcinoma is more common in males than females and is associated with hepatitis B, hepatitis C, chronic alcohol abuse and cirrhosis. Serum elevation of alpha-fetoprotein occurs in a large percentage of patients with hepatocellular carcinoma. Grossly, hepatocellular carcinoma may present as a single mass, as multiple nodules, or as diffuse liver involvement. Microscopically, there is a wide range of differentiation from tumor to tumor (well differentiated to poorly differentiated tumors). Hepatocellular carcinomas quickly metastasize to regional lymph nodes and lung. The overall median survival of untreated liver cell carcinoma is about 4 months. The most effective treatment of hepatocellular carcinoma is complete resection of the tumor. Lately, an increasing number of tumors have been treated with liver transplantation.:Clinical, laboratory or molecular evidence, or absence of evidence of a non-neoplastic disease.:The result of an action.","longName":"C3099:C157510:C20200","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Hepatocellular Carcinoma","conceptCode":"C3099","definition":"A malignant tumor that arises from hepatocytes. Hepatocellular carcinoma is relatively rare in the United States but very common in all African countries south of the Sahara and in Southeast Asia. Most cases are seen in patients over the age of 50 years, but this tumor can also occur in younger individuals and even in children. Hepatocellular carcinoma is more common in males than females and is associated with hepatitis B, hepatitis C, chronic alcohol abuse and cirrhosis. Serum elevation of alpha-fetoprotein occurs in a large percentage of patients with hepatocellular carcinoma. Grossly, hepatocellular carcinoma may present as a single mass, as multiple nodules, or as diffuse liver involvement. Microscopically, there is a wide range of differentiation from tumor to tumor (well differentiated to poorly differentiated tumors). Hepatocellular carcinomas quickly metastasize to regional lymph nodes and lung. The overall median survival of untreated liver cell carcinoma is about 4 months. The most effective treatment of hepatocellular carcinoma is complete resection of the tumor. Lately, an increasing number of tumors have been treated with liver transplantation.","evsSource":"UMLS_CUI","primaryIndicator":"No","displayOrder":"2"},{"longName":"Non-Neoplastic Finding","conceptCode":"C157510","definition":"Clinical, laboratory or molecular evidence, or absence of evidence of a non-neoplastic disease.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Outcome","conceptCode":"C20200","definition":"The result of an action.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9AB144CE-D757-6FE4-E053-F662850A2278","latestVersionIndicator":"Yes","beginDate":"2019-12-27","endDate":null,"createdBy":"KNABLEJ","dateCreated":"2019-12-27","modifiedBy":"ONEDATA","dateModified":"2019-12-27","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"CPTAC: Clinical Proteomic Tumor Analysis Consortium","workflowStatus":"RELEASED","registrationStatus":"Qualified","id":"9AB144CE-D768-6FE4-E053-F662850A2278","latestVersionIndicator":"Yes","beginDate":"2019-12-27","endDate":null,"createdBy":"KNABLEJ","dateCreated":"2019-12-27","modifiedBy":"KNABLEJ","dateModified":"2020-02-14","changeDescription":"2/14/20 jk Released per CPTAC SME (Linda) review and approval. 12/27/19 jk created for CPTAC LIHC baseline CRF.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[{"publicId":"6601273","version":"1","longName":"CPTAC (Clinical Proteomic Tumor Analysis Consortium)","context":"OCCPR","ClassificationSchemeItems":[{"publicId":"6776762","version":"1","longName":"Bile duct and Liver","context":"OCCPR"},{"publicId":"6779541","version":"1","longName":"LIHC Baseline","context":"OCCPR"},{"publicId":"6779542","version":"1","longName":"LIHC Local Pathology","context":"OCCPR"},{"publicId":"6779543","version":"1","longName":"LIHC Pathology Review","context":"OCCPR"}]}],"AlternateNames":[],"ReferenceDocuments":[{"name":"Non-Neoplastic Findings","type":"Preferred Question Text","description":"Non-Neoplastic Findings","url":null,"context":"OCCPR"}],"origin":"CPTAC: Clinical Proteomic Tumor Analysis Consortium","workflowStatus":"RELEASED","registrationStatus":"Qualified","id":"9B0190CA-F682-059E-E053-F662850A482E","latestVersionIndicator":"Yes","beginDate":"2019-12-31","endDate":null,"createdBy":"KNABLEJ","dateCreated":"2019-12-31","modifiedBy":"KNABLEJ","dateModified":"2020-02-14","changeDescription":"2/14/20 jk Released per CPTAC SME (Linda) review and approval.  1/29/20 jk added CSI for LIHC Path Rev and Local CRFs. 12/31/19 jk created for CPTAC LIHC baseline CRF.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"}}